RT @doctorRBC: Deucravacitinib (TYK2i) - phase II trial for PsA âï¸ACR20, 50, 70 responseâï¸HAQ-DI responseâï
Tweet Content
Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
On